Human Chorionic Gonadotropin — NCD 125 | CMS Coverage Update

TL;DR: The Centers for Medicare & Medicaid Services modified NCD 125, the National Coverage Determination governing CMS hCG (human chorionic gonadotropin) testing coverage, effective March 7, 2026. Here's what changes for billing teams.

This update clarifies the medical necessity limits and appropriate use cases for hCG testing under Medicare. The CMS hCG coverage policy draws a hard line between diagnostic testing frequency and monitoring use—and that distinction directly drives your documentation requirements and your exposure to claim denial. The policy does not list specific CPT or HCPCS codes in this version, but your billing team still needs to understand exactly what Medicare will and won't reimburse before you submit another hCG claim.

Quick-Reference Table

CMS hCG Testing Coverage Criteria and Medical Necessity Requirements 2026

NCD 125 in the Medicare system is the National Coverage Determination that governs when Medicare covers human chorionic gonadotropin testing as a diagnostic laboratory service. This coverage policy applies nationally. It is not subject to local coverage determination variation at the Medicare Administrative Contractor level—which means your billing team can't look to your MAC for a more favorable read.

The coverage policy recognizes two distinct clinical contexts for hCG testing, and conflating them is where most billing problems start.

Context 1: Germ cell neoplasm diagnosis and monitoring. CMS covers hCG testing for the diagnosis and monitoring of germ cell neoplasms. These include malignancies of the ovary, testis, mediastinum, retroperitoneum, and central nervous system. This is a straightforward oncology indication with broad clinical acceptance.

Context 2: Obstetric monitoring. CMS also covers hCG for monitoring pregnant patients. The specific criteria are vaginal bleeding, hypertension, and/or suspected fetal loss. Not all pregnancy-related hCG use qualifies—the patient must present with one of these documented clinical conditions.

Here's where medical necessity gets specific: for diagnostic purposes, Medicare will not cover hCG testing more than once per month. That's the hard cap. Testing for monitoring purposes—tracking patient progress and response to treatment—does not carry the same monthly frequency limit. But your documentation must clearly distinguish which purpose the test serves.

This distinction matters for reimbursement. If your oncology practice orders hCG twice in a single month to diagnose a suspected germ cell neoplasm, the second test has no medical necessity support under this coverage policy. CMS will not pay for it, and you won't win that appeal without strong documentation that the second test was for monitoring, not diagnosis.

Whether hCG testing requires prior authorization under Medicare is not addressed in NCD 125 itself. Prior authorization requirements can arise through Medicare Advantage plans that use this NCD as a baseline, so check your specific payer contracts before assuming no prior auth is needed on the MA side.

CMS hCG Testing Exclusions and Non-Covered Indications

One exclusion in NCD 125 is explicit and non-negotiable: qualitative hCG assays are not appropriate for managing patients with known or suspected germ cell neoplasms.

This is worth reading twice. If your provider orders a qualitative hCG—a result that just confirms presence or absence of hCG rather than measuring a specific level—for a patient with a germ cell tumor, Medicare won't cover it. The clinical reason is sound: qualitative assays don't give you the precision you need to monitor tumor markers or treatment response. But the billing implication is that you need to know which assay type was ordered before you submit the claim.

If your lab or ordering provider defaults to a qualitative assay and the patient has a known or suspected germ cell neoplasm, you have a denial waiting to happen. This isn't a gray area—the policy calls it out directly.

Coverage Indications at a Glance

CMS hCG Billing Guidelines and Action Items 2026

The effective date of March 7, 2026 is your starting line. Claims for hCG testing submitted to Medicare on or after this date should align with these updated criteria. Here's what to do before and after that date.

CPT, HCPCS, and ICD-10 Codes for hCG Testing Under NCD 125

NCD 125 does not list specific CPT, HCPCS, or ICD-10 codes within the policy document provided for this update. The policy notes that quarterly covered code lists—including narrative descriptions—are available separately and should be referenced for code-level billing guidance.

This is an important gap. Do not assume that the absence of a code list means all hCG-related codes are covered, or that your current codes are still on the covered list. Quarterly lists can shift codes in and out of covered status without a formal NCD modification.

What this means for your billing team: Check the CMS quarterly covered code list for clinical laboratory services before billing hCG tests under NCD 125. The Medicare Claims Processing Manual, Chapter 120, which covers clinical laboratory services based on negotiated rulemaking, is the cross-reference CMS provides for claims processing instructions under this policy. Your billing team should be familiar with both.

If you bill hCG testing regularly and don't have a process for tracking quarterly code list updates, that's a gap worth closing. A code that was covered last quarter may not be covered this quarter, and NCD 125 won't warn you—the quarterly list will.